Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1

Background. Metformin, as a first-line treatment for diabetes, interacts with many protein kinases and transcription factors which affect the expression of downstream target genes governing drug metabolism. Sulfotransferase, SULT2A1, one phase II metabolic enzyme, sulfonates both xenobiotic and endo...

Full description

Bibliographic Details
Main Authors: Xiaowen Hu, Mengsiyu Li, Chunxue Zhang, Shuguang Pang
Format: Article
Language:English
Published: Hindawi Limited 2021-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2021/8867218
id doaj-44f2633899904d979dee0999b30600a4
record_format Article
spelling doaj-44f2633899904d979dee0999b30600a42021-03-01T01:14:55ZengHindawi LimitedInternational Journal of Endocrinology1687-83452021-01-01202110.1155/2021/8867218Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1Xiaowen Hu0Mengsiyu Li1Chunxue Zhang2Shuguang Pang3Department of EndocrinologyDepartment of UltrasoundDepartment of Nuclear MedicineDepartment of EndocrinologyBackground. Metformin, as a first-line treatment for diabetes, interacts with many protein kinases and transcription factors which affect the expression of downstream target genes governing drug metabolism. Sulfotransferase, SULT2A1, one phase II metabolic enzyme, sulfonates both xenobiotic and endobiotic compounds to accelerate drug excretion. Herein, we designed experiments to investigate the effects and mechanisms of metformin on SULT2A1 expression in vitro. Methods. The hepatocellular carcinoma cell line, HepaRG, was cultured with different concentrations of metformin. The cell viability was measured using CCK8 kit. HepaRG was used to evaluate the protein expression of pregnane X receptor (PXR), the constitutive androstane receptor (CAR), SULT2A1, AMP-activated protein kinase (AMPK), and phosphorylation of AMPK (p-AMPK), respectively, at different concentrations of metformin with or without rifampin (human PXR activator) and CITCO (human CAR activator). The coregulators with CAR on SULT2A1 promoter response elements have also been characterized. Results. We showed that metformin did not affect the basic expression of SULT2A1 but could suppress the expression of SULT2A1 induced by the activator of human CAR. Investigations revealed that metformin which could block CAR nuclear translocation further suppress SULT2A1. In addition, we found that the prevented CAR transfer into the nucleus by metformin was partially an AMPK-dependent event. Conclusion. The present study indicated that the activation of AMPK-CAR pathway mediated the suppression of SULT2A1 by metformin. Metformin may affect the metabolism and clearance of drugs which are SULT2A1 substrates. The results that emerged from this work provide substantial insights into an appropriate medication in the treatment of diabetes patients.http://dx.doi.org/10.1155/2021/8867218
collection DOAJ
language English
format Article
sources DOAJ
author Xiaowen Hu
Mengsiyu Li
Chunxue Zhang
Shuguang Pang
spellingShingle Xiaowen Hu
Mengsiyu Li
Chunxue Zhang
Shuguang Pang
Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1
International Journal of Endocrinology
author_facet Xiaowen Hu
Mengsiyu Li
Chunxue Zhang
Shuguang Pang
author_sort Xiaowen Hu
title Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1
title_short Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1
title_full Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1
title_fullStr Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1
title_full_unstemmed Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1
title_sort constitutive androstane receptor-mediated inhibition of metformin on phase ii metabolic enzyme sult2a1
publisher Hindawi Limited
series International Journal of Endocrinology
issn 1687-8345
publishDate 2021-01-01
description Background. Metformin, as a first-line treatment for diabetes, interacts with many protein kinases and transcription factors which affect the expression of downstream target genes governing drug metabolism. Sulfotransferase, SULT2A1, one phase II metabolic enzyme, sulfonates both xenobiotic and endobiotic compounds to accelerate drug excretion. Herein, we designed experiments to investigate the effects and mechanisms of metformin on SULT2A1 expression in vitro. Methods. The hepatocellular carcinoma cell line, HepaRG, was cultured with different concentrations of metformin. The cell viability was measured using CCK8 kit. HepaRG was used to evaluate the protein expression of pregnane X receptor (PXR), the constitutive androstane receptor (CAR), SULT2A1, AMP-activated protein kinase (AMPK), and phosphorylation of AMPK (p-AMPK), respectively, at different concentrations of metformin with or without rifampin (human PXR activator) and CITCO (human CAR activator). The coregulators with CAR on SULT2A1 promoter response elements have also been characterized. Results. We showed that metformin did not affect the basic expression of SULT2A1 but could suppress the expression of SULT2A1 induced by the activator of human CAR. Investigations revealed that metformin which could block CAR nuclear translocation further suppress SULT2A1. In addition, we found that the prevented CAR transfer into the nucleus by metformin was partially an AMPK-dependent event. Conclusion. The present study indicated that the activation of AMPK-CAR pathway mediated the suppression of SULT2A1 by metformin. Metformin may affect the metabolism and clearance of drugs which are SULT2A1 substrates. The results that emerged from this work provide substantial insights into an appropriate medication in the treatment of diabetes patients.
url http://dx.doi.org/10.1155/2021/8867218
work_keys_str_mv AT xiaowenhu constitutiveandrostanereceptormediatedinhibitionofmetforminonphaseiimetabolicenzymesult2a1
AT mengsiyuli constitutiveandrostanereceptormediatedinhibitionofmetforminonphaseiimetabolicenzymesult2a1
AT chunxuezhang constitutiveandrostanereceptormediatedinhibitionofmetforminonphaseiimetabolicenzymesult2a1
AT shuguangpang constitutiveandrostanereceptormediatedinhibitionofmetforminonphaseiimetabolicenzymesult2a1
_version_ 1714842324271366144